|
DCUN1D1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
6.68440000017867E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
1.63402624764331E-12 |
| Stage1-vs-Stage2 |
4.753600E-01 |
| Stage1-vs-Stage3 |
7.683700E-02 |
| Stage1-vs-Stage4 |
1.942690E-03 |
| Stage2-vs-Stage3 |
6.870100E-02 |
| Stage2-vs-Stage4 |
6.718800E-03 |
| Stage3-vs-Stage4 |
2.145600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.14170911508427E-12 |
| Normal-vs-AfricanAmerican |
5.99719999999637E-05 |
| Normal-vs-Asian |
9.1523455481024E-12 |
| Caucasian-vs-AfricanAmerican |
2.733200E-01 |
| Caucasian-vs-Asian |
5.207400E-01 |
| AfricanAmerican-vs-Asian |
2.298600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.564200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62825308791525E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
2.54740673000242E-12 |
| Normal-vs-Age(81-100Yrs) |
4.765300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.577800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.215400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.644400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.474600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.437800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.179000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.789700E-02 |
| Classical-VS-Follicular |
2.852000E-01 |
| Classical-VS-Other |
7.849400E-01 |
| Classical-VS-Normal |
2.88510326740266E-11 |
| Tall-VS-Follicular |
5.720700E-03 |
| Tall-VS-Other |
3.910200E-01 |
| Tall-VS-Normal |
1.26287869051112E-12 |
| Follicular-VS-Other |
5.716600E-01 |
| Follicular-VS-Normal |
3.50329998344279E-09 |
| Other-VS-Normal |
1.916400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55431223447522E-15 |
| Normal-vs-N1 |
1.0369483049999E-13 |
| N0-vs-N1 |
4.935900E-02 |
|
|
